ERLANGEN, Germany, November 8, 2023 /PRNewswire/ -- Siemens Healthcare recently released results reports for the fourth quarter of fiscal year 2023 and the full year of fiscal year 2023 ending September 30, 2023.

FY2023: Revenue Growth and Earnings Per Share Targets Achieved

• Equipment order shipment ratio reached 1.15
• Excluding the rapid COVID-19 antigen testing business, comparable revenue increased significantly by 8.3%; the rapid COVID-19 antigen testing business was terminated in the fourth quarter. Taking this business into account, comparable revenue increased by 1.2%
• Varian Healthcare's comparable revenue grew strongly by 14.8%; comparable revenue from the imaging business increased by 10.9%, and the comparable revenue from the clinical treatment business increased by 7.8%; due to the termination of the rapid COVID-19 antigen testing business, the laboratory diagnostic business revenue decreased by 24.2%
• Excluding the rapid COVID-19 antigen testing business, the adjusted profit margin before interest and tax was 14.0%, which is basically the same as the same period last year; when calculating the rapid COVID-19 antigen testing business, the adjusted profit margin before interest and tax was 14.2%; due to the low contribution of the rapid COVID-19 antigen testing business, the adjusted profit before interest and tax was reduced to 3.1 billion euros
• Adjusted basic earnings per share amounted to €2.02
• The proposed dividend is €0.95 per share, the same as last year

Fourth quarter of fiscal year 2023: Varian and imaging businesses both achieved double-digit revenue growth, and profits continued to rise

• Excellent equipment order-to-ship ratio of up to 1.16
• Excluding the rapid COVID-19 antigen testing business, comparable revenue increased by 10.8%; taking into account the discontinued rapid COVID-19 antigen testing business, the comparable revenue increased by 7.5%
• Comparable revenue from the video business increased 10.6%; adjusted profit margin before interest and tax reached 22.4%
• Excluding the rapid COVID-19 antigen testing business, the comparable revenue of the laboratory diagnosis business increased by 1.6%; taking into account the rapid COVID-19 antigen testing business that was terminated in the fourth quarter, the comparable revenue of the laboratory diagnosis business decreased by 10.6%; the adjusted profit margin before interest and tax was 2.0%
• Varian Corby's revenue increased by 29.8%; adjusted profit margin before interest and tax was 18.7%
• Comparable revenue from the clinical treatment business increased by 5.1%; adjusted profit margin before interest and tax was 17.5%
• Excluding the rapid COVID-19 antigen testing business, the overall adjusted profit margin before interest and tax reached 16.3%, which is about 160 basis points higher than the same period last year; including the rapid COVID-19 antigen testing business, the overall adjusted profit margin before interest and tax was 16.7%
• Adjusted basic earnings per share of €0.58

2024 outlook

Compared to fiscal year 2023, Siemens Healthcare's comparable revenue for fiscal year 2024 is expected to increase by 4.5% to 6.5%. Excluding the revenue from the rapid COVID-19 antigen testing business, the comparable revenue growth rate is expected to be 5.0% to 7.0%. Adjusted basic earnings per share are expected to be between €2.10 and €2.30.

Meng Tianqi, CEO of Siemens Healthcare ((Bernd Montag): “Siemens Healthcare performed well in the fourth quarter, bringing the 2023 fiscal year to a successful conclusion. I'm very proud of the team's outstanding performance and the trust we've earned from our customers.”

About Siemens Healthcare

Siemens Healthcare (Frankfurt Stock Exchange: SHL), based in Erlangen, Germany, is a leading medical technology company committed to continuously developing a portfolio of products and services, including AI-based applications and digital products that play an increasingly important role in the development of next-generation medical technology. These new applications will further strengthen the company's foundation in the fields of in vitro diagnosis, image-guided treatment, in vivo diagnosis, and novel cancer diagnosis and treatment. At the same time, Siemens Healthcare provides a wide range of services and solutions to help medical service providers improve their capabilities and provide high-quality and efficient services to patients. In fiscal year 2022 (ending September 30, 2022), Siemens Healthcare's total revenue was €21.7 billion and has approximately 69,500 employees worldwide.

An innovative environment, for every life! For more information, visit Siemens Healthcare's official website: